Kimberly-Clark wins EU approval for Kenvue acquisition
Get Alerts KMB Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 5.4%
EPS Growth %: -11.5%
Join SI Premium – FREE
Investing.com -- The European Commission cleared Kimberly-Clark's purchase of Kenvue on Tuesday after the tissue and diaper manufacturer agreed to sell certain feminine hygiene products to address competition concerns.
The maker of Kleenex tissues and Huggies diapers will divest all its tampon and feminine hygiene brands within the European Economic Area as part of the approval conditions, the Commission said in a statement.
The brands included in the divestment are Kotex, which includes the Lidie sub-brand, along with Camelia and Record, according to the EU competition enforcer.
Kenvue manufactures Tylenol pain relief medication.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Softbank Said To Weigh Buying Largest Us Security Firm Allied - Bloomberg
- HDFC Asset Management Co Ltd (HDFCAMC:IN) PT Lowered to INR3,050 at Nomura/Instinet
- US budget deficit widens to $1.99 trillion for fiscal 2026
Create E-mail Alert Related Categories
InvestingRelated Entities
Definitive Agreement, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share